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Abstract
A 29-year-old woman presented with a breast tumor with a primary diagnosis of MALT lymphoma.
A repeat biopsy revealed a hematological neoplasm with diffuse, Indian file, and targetoid patterns.
The cells were intermediate size with eosinophilic granules; the immunophenotyping showed
monocytic differentiation, and no lymphoepithelial lesion was observed. The diagnosis was
granulocytic sarcoma. Three different bone marrow biopsies were negative for neoplastic
infiltration. After treatment, she developed secondary pancytopenia which contributed to her
death 16 months after primary diagnosis. Granulocytic sarcoma of the breast is uncommon. A
complete panel of immunohistochemistry is necessary to perform this diagnosis.
Background
Granulocytic (myeloid) sarcoma (GS) is a rare hematolog-
ical neoplasm composed of immature myeloid cells at an
extramedullary site which may precede leukemia; never-
theless, the most frequent clinical presentation is second-
ary to acute or chronic myeloid leukemia, or
myelodysplastic syndrome [1,2] developing within an
average of 6–12 months after primary diagnosis [3].
The most common sites of presentation of GS are bone,
lymph nodes, soft tissues, and skin; involvement of breast
is uncommon [4-6]. The majority of the cases have been
associated with synchronous or metachronous leukemia.
However, in few published cases, no further disease man-
ifestations developed [1,3,7].
Patients with GS have a poor prognosis, and the majority
of patients without bone marrow infiltration at presenta-
tion die of leukemia within an average of 16.5 months
after diagnosis [2,3].
GS of the breast presents a pattern of infiltration similar to
lobular carcinoma or lymphoma [6-8], as which it is fre-
quently misdiagnosed.
We report the case of a patient with GS involving the
breast with no evidence of a myeloproliferative disease
during the subsequent 16 months, and histological and
immunophenotyping features are needed in order to
avoid misdiagnosis.
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A 29-year-old woman presented with a three month his-
tory of a palpable breast tumor of 3 cm of diameter on the
right side. She underwent a breast biopsy and a primary
diagnosis of MALT type non-Hodgkin lymphoma was ren-
dered in another institution; subsequently, the patient
was treated with 3 cycles of CHOP chemotherapy without
improvement. Three months later, she presented in our
institution with increase of the tumor to 5 × 4 cm. The
peripheral blood showed a white blood cell count of 5.2
G/l, and Hb 12.7 g/l. No blasts cells were identified in the
peripheral blood smear or in bone marrow trephine. She
underwent a radical mastectomy, and after diagnosis, the
patient was treated with radiotherapy (30 Gy to the axil-
lary area with photons and 25 Gy to the thoracic wall with
electrons 15 MeV).
Four months after mastectomy, the tumor relapsed in the
eyelid, abdominal wall, with additional soft tissue infiltra-
tion of the thighs as well as lymph nodes of the left groin.
A repeat bone marrow biopsy was performed and showed
no neoplastic infiltration, and fluorescence in situ hybrid-
ization failed to demonstrate a BCR/ABL translocation.
She received chemotherapy for acute myeloid leukemia
according to the 7+3 scheme with Ara-C (163 mg/day)
and daunorubicin (32 mg/day). Subsequently, she
received radiotherapy and chemotherapy with higher
dose of cytarabin (HIDAC). After treatment, the patient
developed pancytopenia, resulting in hemorrhagic diathe-
sis (echimosis, petechiae and gingivorrhagia) and pneu-
monia. The bone marrow trephine remained negative for
infiltration. The patient developed intracranial hemor-
rhage corroborated by computed tomography, resulting
in deep coma. She expired 16 months after primary diag-
nosis.
Histological and immunohistochemical findings
The assessment of the breast biopsy performed at our
institution showed an infiltrative neoplasm, mainly with
a diffuse pattern that alternated with Indian file or target-
oid pattern. The cells were of intermediate size with scant
cytoplasm, irregular nuclei, clumped chromatin and small
nucleoli; some cells contained eosinophilic granules. Epi-
thelial structures, including ducts and lobules, were pre-
served with surrounding neoplastic cells (targetoid
pattern). Lymphoepithelial lesions were not identified,
not even with immunohistochemical studies (Figure 1B,
1C). Naphtol AS-D chloroacetate esterase was strongly
positive, and mucin stains were negative.
The neoplastic cells showed strong immunoreactivity for
CD68 (KP1), myeloperoxidase, CD34, CD117, CD43,
and lysozyme (Figure 1D); CD45 showed weak staining.
CD3, CD20, CD10, CD15, CD56, CD68 PGM1, bcl-2 and
TdT were negative, as well as epithelial markers (epithelial
membrane antigen, cytokeratin AE1/AE3). The final diag-
nosis was granulocytic sarcoma of the breast, with some
features of monoblastic differentiation, as evidenced by
strong lysozyme expression.
The mastectomy specimen revealed a well-demarcated
tumor measuring 5 × 4 cm, of green color and increased
consistency (Figure 1A). The histological findings were
similar to the biopsy, the axillary dissection showed par-
tial involvement of two lymph nodes. Three repeat bone
marrow biopsies were performed at different times with-
out evidence of neoplastic infiltration.
Discussion
GS of the breast is an unusual site of presentation occur-
ring mainly in young women, with high incidence of
bilaterality [1-3,5]. Mainly, the patients present the breast
engorgement, and a painless mass without associated
local symptoms [1]. In this case, the patient developed a
rapidly growing, non-tender tumor, affecting only the
right breast without bone marrow involvement.
GS of breast shows different patterns of infiltration: dif-
fuse, Indian file, targetoid and starry sky pattern [1]. The
differential diagnosis includes non-Hodgkin lymphoma
(predominantly MALT lymphoma and diffuse large B-cell
lymphoma), lobular carcinoma and small round cell
tumors [2,4,9]. Inflammation and extramedullary hemat-
opoiesis enter into the differential diagnosis when the
maturation of the cells is prominent [10].
In this case, the primary diagnosis was MALT lymphoma,
but the presence of granules, lack of lymphoepithelial
lesions and positivity of granulocytic markers rule out this
possibility [1,4,11].
Lobular invasive carcinoma is the second most frequent
neoplasm of the breast; misdiagnosis is frequent because
GS can present with the same pattern of infiltration. The
presence of carcinoma in situ, droplets of mucin, and loss
of cohesiveness are some histological features to exclude a
GS diagnosis [12], as well as the positivity for epithelial
markers or mucin stains [1,4,11].
A complete panel of immunohistochemistry is helpful to
recognize this entity with an isolated presentation. GS is
immunoreactive for myeloperoxidase, CD117, and
CD68, CD43 is positive in most of the cases, and 75% are
reactive for CD45 [10,13]. Lysozyme and CD68 PGM1
expression are evidence for monocytic differentiation.
Generally, patients with GS develop a myeloproliferative
disease within 6–12 months, nevertheless, in this case the
patient never presented with myeloproliferative or myelo-
dysplastic disease in bone marrow biopsies, and thePage 2 of 4
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months. This is an uncommon phenomenon reported in
few cases [1,3,5,7-9,14-16]. Due to the rarity of isolated
GS and different treatments, the clinical outcome and the
prognosis in this group of patients is hard to predict. In
our patient, the use of the HIDAC regimen, which shows
significant myelotoxicity, lead to severe pancytopenia
which contributed to her death.
Conclusion
GS is an uncommon breast neoplasm, and the clinical
presentation without development of a myeloprolifera-
tive disorder is extremely rare. Ancillary studies are neces-
sary to recognize this entity.
Abbreviations
GS: granulocytic sarcoma; MALT: mucosa associated lym-
phoid tissue
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TV-C participated in conception of the idea, writing of the
manuscript, and interpretation of histological assays. MA-
a) Gross appearance, cut surface solid, green, firm, and well-circumscribedFigure 1
a) Gross appearance, cut surface solid, green, firm, and well-circumscribed. b) Neoplastic cells are surrounding 
without involvement of duct or lobular structures (H&E 100×). c) The cells are of intermediate size with scant cytoplasm, 
irregular nuclei, clumped chromatin, and small nucleoli; some cells contain eosinophilic granules (H&E 400×). d) Myeloperoxi-
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